Aboriginal Cardiovascular Omega 3 Trial
The Aboriginal Cardiovascular Omega 3 Trial seeks to identify if Aboriginal people with heart disease are protected from subsequent heart attacks by taking an Omega 3 supplement, and the mechanisms which occur.
Wardliparingga Aboriginal Research Unit, SAHMRI
Vascular Research Centre, SAHMRI
University of Adelaide
Despite high cardiovascular (CV) mortality among Aboriginal and Torres Strait Islander people, few intervention trials have sought to evaluate novel approaches to reducing differential outcomes. Research to date has focused on traditional risk factors (hypertension, diabetes and hypercholesterolaemia), risk-prone behaviours (smoking, poor diet and sedentary lifestyles), and impaired access to evidence based care. These factors are important, but not sufficient to fully explain such wide disparity.
The Aboriginal Cardiovascular Omega-3 Trial (AC-Omega 3) is a multi-centre, double-blinded, placebo-controlled randomised trial of 1g/day n-3 PUFA supplementation in Aboriginal patients with established coronary artery disease to determine their effect on factors implicated in adverse CV events including:
1. Atherogenic and protective lipid factors implicated in atherosclerosis
2. Inflammatory factors implicated in atherosclerosis
3. Factors associated with thrombus formation
4. Heart rate variability as a marker of arrhythmic risk
5. Major adverse cardiovascular events (MACE)
This project brings together for the first time a team of investigators with extensive experience across Aboriginal health, lipid, sudden cardiac death, platelet function and fatty acid research spanning basic science through clinical and population health paradigms.This is also the first trial to combine mechanistic research specifically designed to understand the role of lipids, thrombosis, inflammation, endothelial function and n-3 PUFAs in adverse outcomes for vulnerable people, alongside a rigorous RCT of a potentially key therapeutic supplement. It is likely to have importance for understanding the leading cause of death and disparity for Aboriginal people, as well as providing rigorous evidence to guide policy and clinical practice.
Professor Alex Brown, Director of Wardliparingga Aboriginal Research Unit, SAHMRI
Professor Stephen Nicholls, Director of the Vascular Research Centre, SAHMRI
Professor Prashanthan Sanders, Knapman Chair of Cardiology Research, University of Adelaide
Professor Robert Gibson, Professor of Functional Food Science, University of Adelaide
Dr. Scott Willoughby, NHMRC Career Development Fellow, University of Adelaide
NHMRC Project Grant
For further information contact Helen Loudis